Legacy Publications. Subject to, and without limitation of, [Section 2.3], Legacy, its Affiliates, Ag Partner, and its Affiliates shall have the right to publish, present or otherwise disclose, including in scientific journals or promotional literature, information pertaining to any Licensed VDC, Viamet Derived Product, CDC, Derivative thereof, or Ag Partner Collaboration Derived Product; provided, however, that the following procedure shall apply: # Legacy shall first provide a copy of the proposed publication or presentation to Primary for review and comment for a period not to exceed forty-five (45) calendar days (the “Legacy Review Period”); # if, during the Legacy Review Period, Legacy receives written notice from Primary identifying Confidential Information of Primary in such a proposed publication or presentation and requesting its deletion, then Legacy shall # delete such Confidential Information from the proposed publication and/or delay such publication or presentation for an additional forty-five (45) calendar days in order to permit such Primary to file a patent application covering such Confidential Information and, with respect to any such publication, presentation, or disclosure proposed by Ag Partner or any Affiliate thereof, # exercise and enforce Legacy’s rights under [Section 10.2(b)] of the Existing Ag Agreement to cause Ag Partner to delete such Confidential Information from the proposed publication and/or delay such publication or presentation for an additional forty-five (45) calendar days in order to permit such Primary to file a patent application covering such Confidential Information.

LegacyPrimary Publications. Subject to, and without limitation of, [Section 2.3], Legacy, its Affiliates, Ag Partner,Primary and its Affiliates shall have the right to publish, present or otherwise disclose, including in scientific journals or promotional literature, information pertaining to any Licensed VDC, Viamet Derived Product, CDC, Derivative thereof, or Ag Partner Collaboration Derived Product, Licensed VDC, or Viamet Derived Product; provided, however, that the following procedure shall apply: # LegacyPrimary shall first provide a copy of the proposed publication or presentation to PrimaryLegacy for review and comment for a period not to exceed forty-seventy-five (45)(75) calendar days (the “Legacy“Primary Review Period”); # if, during the LegacyPrimary Review Period, LegacyPrimary receives written notice from PrimaryLegacy identifying Confidential Information of PrimaryLegacy in such a proposed publication or presentation and requesting its deletion, then LegacyPrimary shall # delete such Confidential Information from the proposed publication and/or delay such publication or presentation for an additional forty-five (45)sixty (60) calendar days in order to permit such Primary to file a patent application covering such Confidential Information and, with respect to any such publication, presentation, or disclosure proposed by Ag Partner or any Affiliate thereof, # exercise and enforce Legacy’s rights under [Section 10.2(b)] of the Existing Ag Agreement to cause Ag Partner to delete such Confidential Information from the proposed publication and/or delay such publication or presentation for an additional forty-five (45) calendar days in order to permit such PrimaryLegacy to file a patent application covering such Confidential Information.